The Foundation
We are working to defeat this disease and achieve a future in which aging is associated with positive experiences.
We are working to defeat this disease and achieve a future in which aging is associated with positive experiences.
I want to help defeat this disease
We talk about Alzheimer's and its impact on those affected and their families.
We believe that only through research will we achieve a future without Alzheimer's.
We work towards changing the social perception of the disease through dissemination and public advocacy.
We put Alzheimer's on the political agenda.
Help us continue investigating.
In this document we collect the most notable activity of 2024, a year of key scientific advances and new strategic alliances that consolidate a change in the approach to Alzheimer's disease
With this addition, the center strengthens its commitment to translational research, aimed at transferring advances from the laboratory to clinical practice
We are strengthening our collaboration to improve the quality of life of people with dementia and their families and communities
This approval is a key step forward in the development of treatments that target the biological mechanisms of Alzheimer's disease.
The research grant has been awarded to the study led by Dr. Silvia De Santis, head of the Translational Imaging Biomarkers group at the Institute of Neurosciences (CSIC–UMH)
Nearly 1,500 people have participated in this initiative that seeks to change the social perception of Alzheimer's
A study involving more than 1,700 people from five hospitals in Barcelona, Sweden, and Italy has validated the usefulness of a blood biomarker for detecting Alzheimer's disease in the clinical setting
The document, developed with the support of the Barcelona Provincial Council, addresses strategies to improve communication, prevent stressful situations and create a stable environment
This recognition highlights his career in preventive medicine and public health, as well as his contribution to research into Alzheimer's prevention
The PMRP 2024 will allocate 1.6 million euros to fund clinical or translational research projects focused on Alzheimer's and other age-related neurodegenerative diseases
Donanemab, approved in the US and other countries, fails to get approval in Europe due to concerns about its adverse effects
Our goal is to provide non-profit organizations with a meeting space in our facilities
